VCYT Q3 2018 Earnings — Veracyte, Inc. Revenue & Financial Results | Market Cap Arena

VCYTVeracyte, Inc.

$3B

Q3 2018 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$23M+33.9% YoY

Gross Profit

$15M64.8% margin

Operating Income

-$4M-18.3% margin

Net Income

-$4M-19.0% margin

EPS (Diluted)

$-0.12

QoQ Revenue Growth

+3.1%

Cash Flow

Operating Cash Flow

-$2M

Free Cash Flow

-$2M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$119M

Total Liabilities

$40M

Stockholders' Equity

$79M

Cash & Equivalents

$78M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$23M	$18M	+33.9%
Gross Profit	$15M	$10M	+46.9%
Operating Income	-$4M	-$6M	+32.4%
Net Income	-$4M	-$7M	+36.6%

Revenue Segments

Service

$250,000100%